Rigel’s 2025 Encore: Strong Product Sales and a 2026 Revenue Forecast Put RIGL in an Optimistic Glass-Half-Full Mood
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) delivered its fourth-quarter and full-year 2025 results, a report that reads like a business-of-the-business memo: commercial momentum, pipeline progress, and a 2026 outlook that leans toward growth. Analysts will be parsing the data for EPS and EPS consensus, while investors watch how a sizable non-cash tax benefit shapes the headline numbers. The company’s ticker, RIGL, is back in focus as management ties revenue forecast to both its flagship products and a late-stage R289 program.
Headline numbers and what they imply
Rigel reports Q4 2025 total revenues of approximately $69.8 million and full-year 2025 total revenues around $294.3 million. Net income for the fourth quarter stood at about $268.1 million and $367.0 million for the full year, aided by roughly $245.9 million of non-cash deferred income tax benefit. Net product sales in Q4 were $65.4 million, with 2025 net product sales at $232.0 million and contract revenues of $62.3 million. In short: the top line grew, and the bottom line benefited from a one-off tax tailwind that investors will want to strip out to see underlying operating performance.
Product portfolio and near-term momentum
The press release highlights continued strength across Rigel’s commercial franchise, including TAVALISSE, GAVRETO, and REZLIDHIA. The numbers imply a favorable near-term trajectory for net product sales, helping to anchor quarterly results even as development milestones loom on the horizon. The question for investors isn’t just “how high” but “how sustainable” — a nuance that matters for EPS and the broader earnings narrative.
Clinical development: R289 and the lower-risk MDS program
On the clinical front, Rigel is continuing enrollment in the dose-expansion phase of the Phase 1b study of R289, its dual IRAK1/4 inhibitor, in relapsed or refractory lower-risk myelodysplastic syndrome (MDS). Management reiterates that it expects to complete enrollment and select a recommended Phase 2 dose in the second half of 2026. It’s a classic move: push the pipeline in a measured way while leveraging commercial strength to fund the expansion play.
Guidance: what to watch for in 2026
The company issued a 2026 outlook with revenues of about $275–$290 million, including net product sales of $255–$265 million, and an expectation for positive net income for the year. This revenue forecast signals continued reliance on portfolio products for growth, with potential upside if R289 delivers a meaningful clinical signal or if pipeline progress unlocks additional indications. The guidance suggests Rigel is aiming for steady top-line expansion, rather than a one-off spike tied to a single product launch.
What this means for investors and peers
From an investor-sentiment perspective, the combination of record 2025 revenue, a robust 2026 revenue forecast, and a clearly staged clinical plan provides a narrative of durability. The absence of an explicit EPS figure in the release means Wall Street will focus on margins, non-cash items, and the tax tailwind’s impact on reported earnings per share. In other words, EPS consensus will be a live conversation as analysts model how operating performance translates into per-share profitability. If Rigel managed to convert this year's revenue strength into a clean, cash-generative 2026, the implied earnings surprise could come from better-than-expected operating margins or from the upside embedded in the R289 program if a Phase 1b signal translates into movement toward a Phase 2 dose selection sooner than anticipated.
CEO tone and strategic takeaway
CEO Raul Rodriguez framed 2025 as a foundation for 2026, underscoring progress across commercial and clinical lines and the plan to advance R289 while continuing to monetize core franchises. The emphasis is not a flashy pivot but a deliberate balance of product strength and pipeline optionality — the kind of posture that makes peers nervous about missing a growth runway, even if the runway has a few tax-induced bumps along the way.
Bottom line and sector implications
Rigel appears to be executing on a strategy that blends a growing product portfolio with a pipeline poised for incremental milestones. For the sector peers, the key takeaway is that a diversified revenue base can support steady earnings and fund late-stage programs without being overly reliant on a single asset. In markets where revenue forecasts and EPS trajectories hinge on biologics and small-molecule combinations, Rigel’s 2025–2026 narrative offers a template: monetize near-term products while pacing clinical milestones that could unlock longer-term growth. As always, the stock market will test whether the non-cash components of the reported net income can be disentangled quickly enough to reveal the real operating story behind the ticker RIGL.